Company intelligence / Profile preview

Cantex Pharmaceuticals, Inc.

Ownership: Private
Employees: ~4
Development stage: Phase 3

Overview

Azeliragon has demonstrated high safety and tolerability in over 2000 patients dosed up to 18 months. It has orphan drug designations for several oncology indications. Ongoing clinical trials include Phase 2 studies in glioblastoma, breast cancer, pancreatic cancer, brain metastases, and a Phase 2/3 trial in hospitalized COVID patients to prevent acute kidney injury. Preclinical data support efficacy across multiple cancers and inflammatory lung diseases.[5][6]

Therapeutic areas: OncologyPulmonologyInfectious Diseases
Modalities: Small molecules (oral RAGE inhibitor)[2][3][5]
Industry: Biotech

Drug pipeline

3 assets

azeliragon

2 more assets in the full pipeline.

Request access →

Partnerships

vTv Therapeutics Inc. (licensing of azeliragon)Harvard University/Wyss Institute

Beyond the preview

Go deeper on Cantex Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cantex Pharmaceuticals, Inc..

Explore the full profile